Core Viewpoint - Citigroup maintains a positive outlook on Ark Health (06086), rating it as "Buy" with a target price of HKD 8.5 [1] Financial Performance - Ark Health forecasts revenue for the previous year to be between RMB 3.5 billion and RMB 3.55 billion, representing a year-on-year growth of 30% [1] - The company expects to turn a profit, with estimated earnings between RMB 7 million and RMB 10 million [1] - Citigroup believes the performance is generally in line with expectations, having previously predicted a 28% revenue growth for 2025 and a net profit of RMB 6 million [1] Growth Drivers - Management attributes the rapid revenue growth to an increase in the number of patients and doctors on the platform [1] - The return to profitability is mainly due to revenue expansion and a reduction in share-based compensation expenses [1] Market Reaction - Ark Health's stock opened significantly higher by 10.25%, reaching a peak of HKD 4.19 [1] - The stock closed at HKD 4.01, reflecting a 41.7% increase, with a trading volume of 118 million shares and a total transaction value of HKD 452 million [1]

Core Viewpoint - Morgan Stanley has raised the target price for JD Health from HKD 60 to HKD 68.8, maintaining a "Market Perform" rating, reflecting positive adjustments based on the company's third-quarter performance [1] Financial Performance - The increase in target price is attributed to growth in direct sales and service revenue, leading to an upward revision of total revenue forecasts for the years 2025 to 2027 by 1.4% [1] - The expansion of drug sales and an increase in the proportion of advertising revenue are expected to enhance the company's gross margin [1] - The forecast for recurring earnings per share has been raised by 9%, 13%, and 13% for the respective years 2025, 2026, and 2027 [1]